From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Commentary|Articles|June 17, 2026
ADA 2026: Lipid Management and Cardiovascular Prevention Updates for People With Diabetes
Fact checked by: Gillian McGovern, Editor
Identifying high-risk patients, optimizing lipid-lowering therapy, and helping patients achieve evidence-based targets remain critical to improving cardiovascular outcomes.
Advertisement
Advertisement
Cardiovascular disease remains the leading cause of morbidity and mortality among people with diabetes. Although advances in glucose-lowering therapies have transformed diabetes management, residual cardiovascular risk remains substantial. At the 86th American Diabetes Association (ADA) Scientific Sessions, several important presentations focused on lipid management and cardiovascular prevention, highlighting both persistent treatment gaps and emerging therapies that may help further reduce cardiovascular risk.
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Advertisement
Advertisement